Home / SmartTech / IBM provides AI tools and resources to corona virus researchers

IBM provides AI tools and resources to corona virus researchers



IBM today announced the launch of services designed to provide researchers with resources to help fight the novel corona virus. The company released molecules identified by AI as therapeutic candidates under an open license and introduced a free version of its Functional Genomics Platform to help discover genome traits. It also provided free access to over 1,000 evidence-based curated content on COVID-19 and infectious diseases, and introduced an AI search engine that was trained on the COVID-19 Open Research Dataset to help researchers quickly find answers to questions.

According to Dario Gil, director of IBM Research, IBM has developed a new AI generative framework that can be used to quickly create new peptides, proteins, drug candidates, and materials that can be used against three goals, around 3,000 new small molecules as Potential to generate COVID-1

9 therapy candidates. Researchers can use an interactive tool to study them to understand their properties and relationship with COVID-19 and to identify molecules that may have desirable properties for drug development.

"The traditional drug discovery pipeline is based on a library of compounds that are being reviewed, improved and tested to determine safety and efficacy," said Gil. "When dealing with new pathogens such as SARS-CoV-2, there is the potential to expand the compound libraries with additional new compounds."

The Functional Genomics Platform complements this with a cloud-based repository of genes, proteins, and other molecular targets from sequenced viral and bacterial organisms with pre-calculated compounds to accelerate the discovery of molecular targets required for drug design, test development, and Treatment is required. Researchers working on COVID-19 can now request access to the interface. Previously, it was only available to government agencies, academic institutions, and other organizations for bacterial studies.

In a similar development, clinicians and healthcare professionals today have access to IBM's COVID-19 content: Micromedex and EBSCO DynaMed, two holistic platforms to support drug information and medical decisions. (Micromedex is used by more than 4,500 hospitals and healthcare systems worldwide, while DynaMed provides expert-reviewed clinical content, including literature research, in 28 specialties.) You can access the latest drug and disease data and provide patient handouts with actionable information.

  VB TRansform 2020: The AI ​​event for managers. San Francisco July 15-16

Finally, IBM trained an AI search system for the COVID-19 Open Research Dataset, which in addition to licensing contains thousands of scientific papers created by the White House and a coalition of research groups from DrugBank and GenBank. The freely available tool extracts embedded text, tables and graphics to answer specific questions from verified researchers.

Watson Assistant for Citizens debuts after IBM provides a map on The Weather Channel to primarily track the spread of COVID-19 using data from governments and the World Health Organization. The company has also created a dashboard based on its Cognos Analytics suite that enables researchers, data scientists and the media to analyze and filter coronavirus information down to the district level.

IBM introduced a chatbot this week that answers coronavirus questions by phone or text, and last week the company announced plans to coordinate efforts to provide researchers with supercomputing capabilities to deliver treatments, viable mitigation strategies, and vaccines to identify for COVID-19. IBM has also launched a new Call for Code Global Challenge that will encourage developers to develop open source technologies that span multiple areas, including emergency crisis communication, ways to improve remote learning, and stimulate collaborative local communities.


Source link